other

Updated:

Mirna Therapeutics

Mirna Therapeutics develops microRNA-based therapies for oncology. The company targets solid and hematologic cancers using miRNA technology to replace or...

Mirna Therapeutics

Mirna Therapeutics develops microRNA-based therapies for oncology. The company targets solid and hematologic cancers using miRNA technology to replace or restore microRNA function. Founded in 2007, Mirna Therapeutics is based in Austin, Texas.

General information

Firm type

other

Location

Region

Asia

Country

China

City

Shanghai

Corporate office

Shanghai, China

Additional offices

Cambridge, United Kingdom · Menlo Park, United States · New York, United States · Seattle, United States · Austin, United States · San Diego, United States

Frequently asked questions

What is Mirna Therapeutics?

Mirna Therapeutics is a firm operating from Shanghai with additional offices in Cambridge (UK), Menlo Park, New York, Seattle, Austin, and San Diego. Its website (mirnarx.com) suggests a focus on therapeutics, but no founding year, named principals, or investment strategy is publicly documented. The firm does not disclose AUM, deployment, or portfolio companies in any public record.

Who runs investment decisions at Mirna Therapeutics?

No named principals or investment decision-makers are publicly traceable for Mirna Therapeutics. The firm's leadership team is not disclosed on its website or in any public source. This absence of disclosure limits external due diligence.

Is Mirna Therapeutics structured as a single family office, multi-family office, or asset manager?

Mirna Therapeutics does not publicly specify its firm type or structure. Based on its name and website, it may operate as a therapeutics-focused investment or operating entity, but no classification — such as single-family office, multi-family office, or asset manager — is confirmed in public records.

What investment stages or sectors does Mirna Therapeutics target?

Mirna Therapeutics does not disclose its target investment stages, sectors, or asset classes in any public source. The firm's name suggests a focus on therapeutics, but no sector tags, stage preferences, or geographic focus beyond its office locations are verifiable.

What is the wealth origin behind Mirna Therapeutics?

The wealth origin of Mirna Therapeutics is not publicly disclosed. No family, principal, or institutional source of capital is attributable in any public record. The firm remains opaque regarding its funding base.

Does Mirna Therapeutics participate in fund commitments or direct deals?

Mirna Therapeutics does not publicly disclose its investment structure, including whether it commits to funds, engages in direct deals, or co-invests alongside external GPs. No associated portfolio companies or deals are documented in public sources.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on investors?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More Shanghai other profiles